Treatment of overactive bladder: Selective use of anticholinergic agents with low drug-drug interaction potential

Geriatrics

Volumn 62, Issue 5, 2007, Pages

  Chancellor, Michael B ^a   De Miguel, Fernando ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anticholinergic drugs; Cytochrome P450; Drug drug interactions; Overactive bladder

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CLARITHROMYCIN; CLOMIPRAMINE; CYCLOSPORIN; CYTOCHROME P450 ISOENZYME; DARIFENACIN; DEXTROMETHORPHAN; DIGOXIN; ERYTHROMYCIN; FLUOXETINE; ITRACONAZOLE; KETOCONAZOLE; METFORMIN; MICONAZOLE; MORPHINE; OMEPRAZOLE; OXYBUTYNIN; PANCURONIUM; PROCAINAMIDE; QUINIDINE; SOLIFENACIN; TENOFOVIR; TESTOSTERONE; TOLTERODINE; TROLEANDOMYCIN; TROSPIUM CHLORIDE; VANCOMYCIN; VINBLASTINE; WARFARIN;

DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HUMAN; LIVER DISEASE; OVERACTIVE BLADDER; REVIEW;

BENZHYDRYL COMPOUNDS; CHOLINERGIC ANTAGONISTS; CRESOLS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; NORTROPANES; PHENYLPROPANOLAMINE; URINARY BLADDER, OVERACTIVE;

EID: 34249732559     PISSN: 0016867X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Wein AJ. Pharmacological agents for the treatment of urinary incontinence due to overactive bladder. Expert Opin Investig Drugs. 2001;10(1):65-83.
2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327-336.
3. Stewart K, McGhan WF, Offerdahl T, et al. Overactive bladder patients and role of the pharmacist. J Am Pharm Assoc (Wash). 2002;42(3):469-478.
4. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48(2):133-143.
5. Pak RW, Petrou SP, Staskin DR. Trospium chloride: a quaternary amine with unique pharmacologic properties. Curr Urol Rep. 2003;4(6):436-440.
6. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18(1):84-112.
7. Guay DR. Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy. 1999; 19(3):267-280.
8. Postlind H, Danielson A, Lindgren A, et al. Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos. 1998;26(4):289-293.
9. Brynne N, Bottiger Y, Hallen B, et al. Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. Br J Clin Pharmacol. 1999;47(2):145-150.
10. Dmochowski R, Chen A, Sathyan G, et al. Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. J Clin Pharmacol. 2005;45(8):961-968.
11. Colucci VJ, Rivey MP. Tolterodine-warfarin drug interaction. Ann Pharmacol. 1999;33(11):1173-1176.
12. Brynne N, Forslund C, Hallen B, et al. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity. Br J Clin Pharmacol. 1999;48(4):564-572.
13. Brynne N, Svanstrom C, Aberg-Wistedt A, et al. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance. Br J Clin Pharmacol. 1999;48(4):553-563.
14. Detrol [package insert]. Kalamazoo, Mich: Pharmacia & Upjohn; rev 2003. Available at: http://www.pdr.net. Accessed April 27, 2007.
15. Yaich M, Popon M, Medard Y, et al. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics. 1998;8(5):449-451.
16. Lukkari E, Juhakoski A, Aranko K, et al. Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite. Eur J Clin Pharmacol. 1997;52(5):403-406.
17. Grozinger M, Hartter S, Hiemke C, et al. Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. J Clin Psychopharmacol. 1999;19(3):287-289.
18. Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 1992;22(7):859-869.
19. Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000;38(5):223-234.
20. Sanctura [package insert]. East Hanover, NJ, and Lexington, Mass: Odyssey Pharmaceuticals, Inc, and Indevus Pharmaceuticals, Inc; 2004.
21. Kerbusch T, Wahlby U, Milligan PA, et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br J Clin Pharmacol. 2003;56(6):639-652.
22. Kuipers M, Smulders R, Krauwinkel W, et al. Open-label study of the safety and pharmacokinetics of solifenacin in subjects with hepatic impairment. J Pharmacol Sci. 2006;102(4):405-412.